SLC7A11 and epilepsy: Through a series of in vivo and in vitro experiments, we provide evidence that targeting xCT and YTHDC2 in reactive astrocytes significantly reduces extracellular glutamate and mitigates seizure activity, offering novel therapeutic targets for epilepsy treatment.